Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-aventis has settled US patent infringement suits related to generic versions of Eloxatin (oxaliplatin) with certain defendants involved in the litigation.
Subscribe to our email newsletter
The lawsuits relate to the quality and formulation of Oxaliplatin, available in the US under the brand name Eloxatin. The settlement agreements are subject to review by the Federal Trade Commission, the US Department of Justice and the Attorney General for the State of Michigan.
Sanofi and Debiopharm, licensor of the involved patent rights, signed settlement agreements with Teva Pharmaceuticals, Fresenius Kabi (formerly Dabur) and Sandoz (Generic manufacturers), thus partially resolving the litigation over certain formulations of Eloxatin (oxaliplatin) in the US District Court for the District of New Jersey and the US District Court for the District of Columbia.
As per the terms of the proposed settlement, the generic manufacturers would cease selling their generic Oxaliplatin products on June 30, 2010, and would resume selling generic Oxaliplatin products on August 9, 2012, under a license to re-enter the market.
Sanofi-aventis has reported that all of the settlement provisions, including the dates noted above, are subject to contingencies which could enhance, diminish or eliminate the value of those settlements to the Group.